A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck

Tomohiro Enokida | Takenori Ogawa | Akihiro Homma | Kenji Okami |
Shujiro Minami | Ayako Nakanome | Yasushi Shimizu | Daisuke Maki |
Yuri Ueda | Takao Fujisawa | Atsushi Motegi | Akira Ohkoshi |
Koji Ebisumoto | Shogo Nomura | Susumu Okano | Makoto Tahara

1Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan
2Department of Otolaryngology – Head and Neck Surgery, Tohoku University School of Medicine, Miyagi, Japan
3Department of Otolaryngology, Head & Neck Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
4Department of Otolaryngology – Head Neck Surgery, Tokai University, Kanagawa, Japan
5Department of Otolaryngology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
6Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Japan
7Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan
8Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Chiba, Japan

Correspondence
Makoto Tahara, Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
Email: matahara@east.ncc.go.jp

Abstract

Background: Induction chemotherapy (IC) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) often compromises compliance with subsequent chemoradiotherapy (CRT), which negatively affects outcomes. Here, we assessed the combination of paclitaxel (PTX), carboplatin (CBDCA), and cetuximab (Cmab) as IC for unresectable LA-SCCHN.

Methods: Induction chemotherapy consisted of weekly CBDCA area under the plasma concentration-time curve $= 1.5$, PTX $80 \text{mg/m}^2$ and Cmab with an initial dose of $400 \text{mg/m}^2$ followed by $250 \text{mg/m}^2$ for 8 weeks. Following IC, CDDP ($20 \text{mg/m}^2$, 4 days $\times$ 3 cycles) and concurrent radiotherapy ($70 \text{Gy/35 fr}$) were started. Primary endpoint was the proportion of CRT completion ($\%$CRT completion). PCE was planned to be deemed effective if the Bayesian posterior probability (PP), defined as the probability that $\%$CRT completion was larger than the threshold value of 65%, exceeded 84%.

Results: Thirty-five patients were enrolled. Cases were hypopharynx/oropharynx/larynx in 17/17/1 patients, all at Stage IV. Of 35 patients, 34 (97%) completed IC and 32 received CRT and met the criteria of full analysis set (FAS). In FAS, the $\%$CRT completion was 96.9%, and PP was 99.9%, exceeding the prespecified boundary of 84%. Mean cumulative dose and relative to dose intensity of CDDP in CRT was $232.5 \text{mg/m}^2$ and 100%, respectively. Response rate was 88.6% by IC and 93.8% in the CRT phase. Three year overall survival was 83.5%. Main grade 3 toxicities included neutropenia (11.4%) and skin rash (5.7%) during IC; and oral mucositis (31.3%) and neutropenia (12.5%) during CRT. No grade 4 toxicity or treatment-related death was seen.
1 | BACKGROUND

Head and neck cancers (HNC) are the sixth-most common cancer in the world, and approximately 650,000 new cases are projected annually. An estimated 60% of these patients present with locally advanced disease (stage III/IV). Standard treatment for unresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is concurrent chemoradiotherapy (CRT). However, a significant number of cases will recur, particularly those with higher nodal status at presentation, indicating a clear need for further therapeutic intervention in this population.

Induction chemotherapy (IC) may improve the prognosis of LA-SCCHN. Several studies have shown that IC consistently results in higher response and exerts a pronounced effect on distant metastases. In several phase III trials, combination of docetaxel, cisplatin (CDDP), and 5-fluorouracil (TPF) improved clinical response and survival compared with CDDP and 5-fluorouracil (PF) alone, and this regimen is now considered the accepted standard of care for IC. However, because no study featured CRT with CDDP in the control arm, the addition of IC (TPF) to CDDP-based CCRT (sequential CRT) has not been shown to be superior to CDDP-based CCRT alone. More importantly, discussion continues over whether sequential CRT can be safely administered and whether its compliance can be assured given the significant toxicities of induction TPF. In TAX 324, 21% of patients (49/255 patients) did not proceed to per-protocol carboplatin (CBDCA) plus RT, while in TAX323, approximately 25% of patients did not complete all cycles of full-dose TPF. Additionally, induction TPF-associated death is reported up to 5%. Since CRT is the definitive standard treatment, an obvious concern is that aggressive treatment, herein induction TPF followed by CRT with CDDP, might not ultimately improve outcomes if the entire treatment, especially the CRT component, cannot be completed.

2 | PATIENTS AND METHODS

See Supporting Information for more details.

2.1 | Patients

For inclusion, patients were required to meet all of the following criteria: histologically proven squamous cell carcinoma; primary lesion located at the oropharynx, hypopharynx or larynx; and unresectable locally advanced HNC that fulfills at least one of the following conditions: (a) primary lesion or cervical lymph node metastasis invasion to the carotid artery, cranial base, or cervical vertebrae; (b) cervical lymph node metastasis of N2b involving the lower neck (Level IV or supraclavicular lymph node), N2c or N3 (UICC⁄TNM, 7th edition); or (c) T4 primary lesion located at the oropharynx.

2.2 | Treatment and assessment

The protocol treatment consisted of IC followed by concurrent CRT, and salvage surgery if applicable. First, patients received IC consisting of CBDCA area under the plasma concentration-time curve (AUC) = 1.5, PTX 80 mg/m² and Cmab with an initial dose of 400 mg/m² followed by 250 mg/m² administered weekly for 8 weeks. If the physician omitted a cytotoxic drug (CBDCA or PTX), they could continue PCE until the number of administrations of cytotoxic drug (either CBDCA or PTX) reached eight, within 10 weeks after the start of IC. Prophylactic use of granulocyte-colony stimulating factor (G-CSF) was permitted if PCE was not given due to neutropenia in the preceding course. Following IC, CDDP and concurrent radiotherapy.

Conclusions: PCE as IC was feasible, with promising efficacy and no effect on compliance with subsequent CRT in unresectable LA-SCCHN.

Keywords: carboplatin, cetuximab, chemoradiotherapy, induction chemotherapy, paclitaxel, unresectable locally advanced squamous cell carcinoma of the head and neck
were started. Chemotherapy consisted of a 2-hour infusion of CDDP at a dose of 20 mg/m²/d on days 1-4, repeated three times at 3-week intervals, giving a planned total CDDP dose during CRT of 240 mg/m². Radiation therapy was carried out once daily with 70 Gy/35 fractions over 7 weeks using high-energy photons of 4-10 MV X-rays and intensity-modulated radiotherapy planning, starting on day 1. Objective response was evaluated using the modified RECIST criteria.

2.3 | Study design

The study was conducted under a multicenter, prospective, single-arm phase II design to assess the feasibility and efficacy of PCE as IC for unresectable LA-SCCHN. Our primary purpose was to assess whether induction PCE compromises compliance with subsequent CDDP-based CRT. The study protocol was approved by the institutional review board of each participating institution and registered with the UMIN Clinical Trials Registry, number UMIN000014430. Primary endpoint was the proportion of CRT completion (%CRT completion), defined by (a) completion of planned CDDP relative to dose intensity (RDI) ≥80%; and (b) completion of radiotherapy within 2 weeks after the planned completion date.

2.4 | Statistical analysis

Our primary aim was to examine whether compliance with CDDP-based CRT is not worse when experimental PCE is given as IC. During planning, we retrospectively collected individual data of 75 patients who had undertaken CDDP-based CRT without any IC at an institution of the first author (National Cancer Center Hospital East), and found that %CRT completion was 81% (see Doc. S1 for background information on the cohort). Accordingly, the threshold and expected values of %CRT completion were set as 65% and 80%, respectively. When Bayesian posterior probability (PP) that %CRT completion exceeds 65% was more than 84%, PCE as IC was planned to be deemed effective, or otherwise ineffective. Using the weakly informative beta distribution of Beta(1,1) as prior distribution, required sample size of the full analysis set (FAS) was calculated as 31.22 Numerical simulation with 10,000 iterations showed type-I and type-II error rates of 18.9% and 15.3%, respectively. Full analysis set was defined to include patients who accomplished induction PCE therapy within the protocol-defined dose reduction criteria and who were treated with CDDP-based CRT at least once. Considering that a few patients might not meet FAS criteria, we enrolled 4-5 additional patients. When the number of patients meeting the FAS criteria exceeded 31, the same decision criteria for declaring efficacy was planned to be used.

3 | RESULTS

3.1 | Patients and disease characteristics

From July 2014 to July 2017, 35 eligible patients were accrued from 5 sites (32 males and 3 females; median age 63 years). Characteristics and stage distribution are listed in Table 1 and Figure S1, respectively. All patients had neck lymph node involvement with low neck N2b, and N2c or worse. The most common primary site was the oropharynx and larynx (both 49%, 17/35). p16 staining as a surrogate for human papilloma virus (HPV) was reported as an adendum to pathology reports from patient specimens. Nine (53%) of 17 patients tested positive. A total of 32 patients (91.4%) were current drinkers and 30 (85.7%) had a history of tobacco use, of whom 90% had a ≥10 pack-year smoking history. Accordingly, at least 88% of oropharyngeal cancer patients among FAS cases (14/16 patients) were considered either intermediate- or high-risk populations, as defined by the Radiation Therapy Oncology Group (RTOG) 0129 criterion²³ (Figure S2). All patients underwent prophylactic percutaneous endoscopic gastrostomy feeding tube placement before starting CRT.

3.1.1 | Treatment and CRT completion rate

All 35 enrolled patients proceeded to IC (safety population; SP) (Figure 1). Of 35 SP patients, 34 completed IC. One discontinued IC due to prolonged grade 2 serum alanine aminotransferase (ALT) elevation. A majority of the patients received the full course of induction PCE as planned per protocol in terms of the number of drug administrations and dose intensity (Table S1). Three patients (8.6%) received G-CSF support after omission of treatment due to neutropenia in a prior cycle. Two of 34 patients who completed IC did not start CRT, one each due to disturbed performance status caused by disease progression and peritonitis related to placement of the PEG. In total, 32 received CRT (FAS).

In FAS, mean cumulative dose and RDI of CDDP during CRT was 232.5 mg/m² (range: 160-240 mg/m²) and 100% (range: 66.7%-100%), respectively (Table 2). Only one patient did not receive CDDP above 200 mg/m² due to grade 3 mucositis and impaired PS from 0 to 2. The remaining patient omitted radiotherapy on 1 day due to mucosal infection. All FAS cases completed planned radiotherapy. Thus, %CRT completion was 96.9% (31/32, 95% CI, 83.8%-99.9%, 95 credible interval, 86.3%-99.8%). Bayesian PP
### Table 1: Patient demographics and clinical characteristics

| Characteristic                                   | SPa (n = 35) |  | FAS (n = 32) |  |
|--------------------------------------------------|--------------|---|--------------|---|
| Median age (range)                               | 63 (41-72)   | — | 63.5 (41-72) | — |
| **Sex**                                          |              |   |              |   |
| Male/female                                     | 32/3         | 91.4/8.6 | 29/3         | 90.6/9.4 |
| **Staging**                                      |              |   |              |   |
| Stage IVa/IVb                                    | 27/8         | 77.1/22.9 | 24/8         | 75/25 |
| T4                                              | 18           | 51.4 | 17           | 53.1 |
| N3                                               | 4            | 11.4 | 4            | 12.5 |
| **Site of primary tumor**                        |              |   |              |   |
| Oropharynx                                       | 17           | 48.6 | 16           | 50.0 |
| Hypopharynx                                      | 17           | 48.6 | 15           | 46.9 |
| Larynx                                          | 1            | 2.9  | 1            | 3.1  |
| **p16 status for oropharyngeal cancer**          |              |   |              |   |
| p16-positive                                     | 9            | 25.7 | 9            | 28.1 |
| p16-negative                                     | 2            | 5.7  | 2            | 6.3  |
| Unknown                                          | 6            | 17.1 | 5            | 15.6 |
| **Reason for unresectability**                   |              |   |              |   |
| Inoperable                                       | 10           | 28.6 | 10           | 31.3 |
| N status                                         | 25           | 71.4 | 23           | 71.9 |
| T4 oropharyngeal origin                          | 11           | 31.4 | 10           | 31.3 |
| **RTOG 0129 risk group for oropharyngeal cancer**|              |   |              |   |
| Low risk                                         | 0            | 0    | 0            | 0    |
| Intermediate or high risk⁶                       | 15           | 88.2 | 14           | 87.5 |
| Low risk or high risk⁶                           | 2            | 11.8 | 2            | 12.5 |
| **Smoking status**                               |              |   |              |   |
| Never                                           | 5            | 14.3 | 5            | 15.6 |
| Former                                          | 15           | 42.9 | 15           | 46.8 |
| Current                                         | 15           | 42.9 | 12           | 37.5 |
| **Cigarette smoker (pack years)**                |              |   |              |   |
| <10                                              | 3            | 10   | 3            | 11.5 |
| ≥10                                              | 27           | 90   | 23           | 88.5 |
| Smoking consumption [pack years] mean ± SD (range)| 24.3 ± 20.3 (0-76.5) | —  | 23.9 ± 21.1 (0-76.5) | — |
| **Alcohol status**                               |              |   |              |   |
| Never                                           | 3            | 8.6  | 4            | 12.5 |
| Former                                          | 0            | 0    | 0            | 0    |
| Current                                         | 32           | 91.4 | 28           | 87.5 |
| Alcohol consumption [drink/wk] mean ± SD (range) | 14.7 ± 16.2 (0-56) | —  | 15.0 ± 16.9 (0-56) | — |

Abbreviations: FAS, full analysis set; SD, standard deviation.

⁷Safety population (equivalent to total population).

⁷Depending on p16 status.

⁷Among former or current smokers.

⁷Data were available for 33 of 35 patients. One drink contains 10 g of pure alcohol.
was 99.9%, which exceeded the prespecified cutoff value of 84%, and the primary objective of this study was therefore met (Table 2).

### 3.2 Treatment outcomes

Efficacy data are listed in Table 3. All enrolled patients were assessable for response at least once. Overall response rate was 88.6% (31/35), with 0 CR and 31 PR in the IC phase; and 93.8% (31/32), with 11 CR, 14 good PR, and 5 PR in the CRT phase, respectively. Accordingly, clinical complete remission rate at CRT completion was 78.1% (25/32). After a median follow-up of 1.89 years (range: 1.19-3.26 years) for FAS, 3-year OS was 83.5% with a 3-year event-free survival (EFS) of 38.2%, 3-year time-to-local progression (TTLP) of 51.9% and 3-year time-to-distant metastasis (TTDM) of 16.7% (Figure 2; prognosis data of SP are presented in Figure S3). In survival analyses according to oropharyngeal primary vs others, p16 status among oropharyngeal cancer patients and CR vs good PR showed no statistically significant difference in clinical outcomes (Figure 3). At data cut-off, 16 patients had disease progression, including locoregional site disease only (n = 11), distant metastatic disease (n = 3), or both (n = 2) (Figure S4). Among them, one patient who did not achieve CR or good PR at the time of CRT completion received R0 salvage surgery as protocol treatment, and the other five received off-protocol salvage surgery for late locoregional recurrence. Accordingly, six (37.5%) of the 16 patients received salvage surgery with curative intent because of the absence of distant metastasis (DM): five received salvage neck dissection for cervical node disease and one received salvage laryngectomy for local recurrence of hypopharyngeal cancer. Systemic chemotherapy was carried out in nine patients as first-line treatment for disease progression, all of which were off-protocol.
Overall toxicities during IC and CRT are listed in Tables 4 and 5, respectively. The most common grade 3 toxicity during IC was neutropenia (11.4%), followed by leukopenia (8.6%), rash (5.7%), and anemia (5.7%). During CRT, the most common grade 3 toxicities were mucositis (31.3%), radiation dermatitis (12.5%), neutropenia (12.5%), leukopenia (12.5%), and dysphagia (9.4%). There were no instances of febrile neutropenia (FN), and no grade 4 toxicity or treatment-related death. Total frequency of grade 3 or more toxicity was 14.2% in IC and 43.6% in CRT. Late toxicity was evaluable in 29 cases, and median time from completion of treatment to evaluation was 12 months (range: 6-29). The most common late toxicities were dry mouth (72.4%) and dysgeusia (51.7%), but most of these were grade 1 or 2. Total frequency of grade 3 or more late toxicity was 10.3% (Table S2).

3.3 Toxicity

Overall toxicities during IC and CRT are listed in Tables 4 and 5, respectively. The most common grade 3 toxicity during IC was neutropenia (11.4%), followed by leukopenia (8.6%), rash (5.7%), and anemia (5.7%). During CRT, the most common grade 3 toxicities were mucositis (31.3%), radiation dermatitis (12.5%), neutropenia (12.5%), leukopenia (12.5%), and dysphagia (9.4%). There were no instances of febrile neutropenia (FN), and no grade 4 toxicity or treatment-related death. Total frequency of grade 3 or more toxicity was 14.2% in IC and 43.6% in CRT. Late toxicity was evaluable in 29 cases, and median time from completion of treatment to evaluation was 12 months (range: 6-29). The most common late toxicities were dry mouth (72.4%) and dysgeusia (51.7%), but most of these were grade 1 or 2. Total frequency of grade 3 or more late toxicity was 10.3% (Table S2).

4 DISCUSSION

This phase II trial evaluated induction PCE and concurrent CRT with CDDP as per study design in a heterogeneous group of patients with unresectable LA-SCCHN. Results showed the high feasibility of subsequent therapy, represented by a %CRT completion of 96.9%. In addition, considerable efficacy was seen, with a %CR at CRT completion of 78.1% and 3-year OS of 83.5% in a patient population harboring far-advanced disease with a heavy smoking and drinking history.

The question of whether TPF followed by concurrent CRT with CDDP can be safely administered with assured compliance has been discussed. The prospective phase II, single-arm Southwest Oncology Group study (S0216) treated 74 LA-SCCHN patients with two cycles of induction TPF, followed by concurrent CRT with CDDP 100 mg/m² on days 1 and 22. Despite two cycles of CDDP during CRT, only 50 (68%) of 74 patients completed all planned treatment; notably, 11 (18%) of 61 patients who started CRT could not finish. In our study, in contrast, 34 of 35 patients (97.1%) completed induction PCE, and only one of 32 FAS patients (3%) who started CRT were unable to complete it owing to toxicity. Moreover 63 patients (85%) in S0216 experienced grade 3 or higher toxicities, including 13 (18%) who required hospitalization for FN under prophylactic ciprofloxacin and two treatment-related deaths, one each due to FN and a cardiac cause during IC. Furthermore, there were two
additional toxicity-related deaths during CRT, one from FN and the second from a cardiac cause. In contrast, we saw no FN, grade 4 toxicity or treatment-related death in the present study, even though primary prophylactic G-CSF support and prophylactic antibiotics were not permitted, and use of secondary prophylactic G-CSF against neutropenia (8.3%) was limited throughout the IC phase. Grade 3 or higher toxicity was much less frequent than in S0216 (14.2% vs 85% in IC, 43.6% vs 91% in CRT, respectively). These findings are more frequently seen in daily practice. Guguillaume et al retrospectively reported toxicities during three or four cycles of induction TPF in LA-SCCHN: among patients with induction TPF, 11% discontinued IC at the first cycle of TPF and 15% discontinued IC at the second cycle of TPF, primarily due to treatment-related toxicity. Moreover 36.1% experienced renal failure (grade 3 in 14.7%), which often and directly compromised subsequent CRT (vs grade 1 in 2.9% in the current study). In addition, 37% developed diarrhea, likely due to continuous infusion of fluorouracil, whereas no patient experienced diarrhea in our present study. The excellent toxicity profile of induction PCE would likely lead to excellent compliance of subsequent CRT with CDDP.
Although IC was added prior to CRT, 96.9% achieved more than 200 mg/m² CDDP during CRT, which was considered an appropriate cumulative dose to show a significant survival benefit compared with RT alone independent of CDDP schedule.26,27 Very recently, Haddad et al reported a phase II clinical trial with randomization to PCE and combination of Cmab and TPF (C-TPF), followed by treatment at the local physician's discretion in patients with LA-HNSCC.28 Mean RDI during PCE in their study was similar to that in our present study (Table S1), with manageable toxicities and no treatment-related deaths. Moreover the number of patients who received CRT with CDDP as post-IC local therapy (n = 15, not as per study design) was significantly higher in the PCE versus C-TPF arm (52% vs 20%; P = .001), suggesting increased toxicity with CDDP and RT in the post-TPF setting. Additionally, unexpected RT omission and accompanying prolongation of radiation treatment time, which negatively affect local control and survival in patients treated with
CRT, were observed in only one patient and by one day. As CRT is the standard therapy for unresectable LA-SCCHN and increases cure rates compared with RT alone, preservation of the intended treatment plan and the ability to receive sufficient CDDP and a full dose of RT should help maximize favorable outcomes. Given this, the current PCE regimen followed by CRT with CDDP is a well-balanced treatment.

Although induction PCE was less toxic than TPF and the patients had far advanced disease, response to IC (ORR 88.6%) was preserved; RR to TPF in TAX 323 and TAX 324 was 68% and 72%, respectively. Furthermore, the 3-year OS of 83.5% is a promising result for an unresectable LA-SCCHN population; 2-year OS in the TPF arm in TAX 323 and 3-year OS to the CRT with CDDP (without prior IC) arm in the Adelstein study was 43% and 37%, respectively.2,9 The appearance of DM after definitive CRT in LA-SCCHN is almost invariably fatal: the overall 5-year survival rate for patients who developed DM after CRT is 0% vs 51.6% for patients without DM.30 Induction chemotherapy in patients with a high risk of DM appear to gain certain benefits from the sequential CRT approach, since IC offers theoretical benefits with the potential to reduce the risk of distant metastases by eradication of micrometastatic disease, which can confer a survival benefit.

### Table 4: Selected toxicity during induction chemotherapy

|                      | All grade | Grade 3 | Grade 4 |
|----------------------|-----------|---------|---------|
| **Hematologic**      |           |         |         |
| Leukopenia (%)       | 32 (91.4) | 3 (8.6) | 0 (0)   |
| Neutropenia (%)      | 28 (80)   | 4 (11.4) | 0 (0)   |
| Anemia (%)           | 24 (68.6) | 2 (5.7) | 0 (0)   |
| Thrombocytopenia (%) | 1 (2.9)   | 0 (0)   | 0 (0)   |
| Febrile neutropenia  | 0 (0)     | 0 (0)   | 0 (0)   |
| **Non-hematologic**  |           |         |         |
| Infusion reaction (%)| 3 (8.6)   | 1 (2.9) | 0 (0)   |
| Allergic reaction (%)| 3 (8.6)   | 1 (2.9) | 0 (0)   |
| Nausea (%)           | 3 (8.6)   | 0 (0)   | —       |
| Anorexia (%)         | 6 (17.1)  | 1 (2.9) | 0 (0)   |
| Mucositis (%)        | 11 (31.4) | 0 (0)   | 0 (0)   |
| Fatigue (%)          | 19 (54.3) | 1 (2.9) | —       |
| Constipation (%)     | 13 (37.1) | 0 (0)   | 0 (0)   |
| Peripheral neuropathy| 14 (40.0) | 1 (2.9) | 0 (0)   |
| Alopecia (%)         | 27 (77.1) | —       | —       |
| Rash (%)             | 32 (91.4) | 2 (5.7) | 0 (0)   |
| Paronychia (%)       | 12 (34.3) | 0 (0)   | —       |
| Other skin (%)       | 23 (65.7) | 0 (0)   | 0 (0)   |
| Pneumonia (%)        | 1 (2.9)   | 0 (0)   | 0 (0)   |
| Pneumonia (%)        | 1 (2.9)   | 1 (2.9) | 0 (0)   |
| Soft tissue infection| 2 (5.7)   | 0 (0)   | 0 (0)   |
| Hypomagnesemia (%)  | 12 (34.3) | 0 (0)   | 0 (0)   |
| Acute kidney injury (%) | 1 (2.9) | 0 (0)   | 0 (0)   |
| AST elevation (%)    | 8 (22.9)  | 0 (0)   | 0 (0)   |
| ALT elevation (%)    | 21 (60.0) | 0 (0)   | 0 (0)   |
| **Total with ≥Grade 3 toxicity** | 5 (14.2) |         |         |

**Note:** Graded according to common toxicity criteria for adverse events version 4.0.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase.

*a*SP (safety population).

*b*Including seborrheic dermatitis, dry skin, pruritus and skin cracks.

### Table 5: Selected toxicity during chemoradiotherapy

|                      | All grades | Grade 3 | Grade 4 |
|----------------------|-----------|---------|---------|
| **Hematologic**      |           |         |         |
| Leukopenia (%)       | 32 (100)  | 4 (12.5) | 0 (0)   |
| Neutropenia (%)      | 28 (87.5) | 4 (12.5) | 0 (0)   |
| Anemia (%)           | 31 (96.9) | 2 (6.3)  | 0 (0)   |
| Thrombocytopenia (%) | 11 (34.4) | 0 (0)   | 0 (0)   |
| Febrile neutropenia  | 0 (0)     | 0 (0)   | 0 (0)   |
| **Non-hematologic**  |           |         |         |
| Radiation dermatitis | 30 (93.8) | 4 (12.5) | 0 (0)   |
| Mucositis (%)        | 32 (100)  | 10 (31.3) | 0 (0)   |
| Dysgeusia (%)        | 31 (96.9) | —       | —       |
| Dysphagia (%)        | 18 (56.3) | 3 (9.4)  | 0 (0)   |
| Dry mouth (%)        | 26 (81.3) | 0 (0)   | —       |
| Mucosal infection (%)| 2 (6.3)   | 0 (0)   | 0 (0)   |
| Soft tissue infection| 2 (6.3)   | 1 (3.1)  | 0 (0)   |
| Pneumonia (%)        | 1 (3.1)   | 0 (0)   | 0 (0)   |
| Nausea (%)           | 16 (50)   | 1 (3.1)  | —       |
| Anorexia (%)         | 14 (43.8) | 1 (3.1)  | 0 (0)   |
| Fatigue (%)          | 14 (43.8) | 0 (0)   | —       |
| Peripheral neuropathy| 13 (40.6) | 0 (0)   | 0 (0)   |
| Acute kidney injury (%) | 11 (34.4) | 0 (0)   | 0 (0)   |
| AST elevation (%)    | 7 (21.9)  | 0 (0)   | 0 (0)   |
| ALT elevation (%)    | 15 (46.9) | 0 (0)   | 0 (0)   |
| Hypomagnesemia (%)  | 14 (43.8) | 0 (0)   | 0 (0)   |
| **Total with ≥Grade 3 toxicity** | 14 (43.6) |         |         |

**Note:** Graded according to common toxicity criteria for adverse events version 4.0.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase.

*a*FAS (full analysis set).
effect was particularly expected in patients with advanced nodal disease, such as multiple involved large-volume nodal disease, and low nodes. Bhatassali et al reported the significance of nodal status from the viewpoint of IC in p16-positive oropharyngeal cancer. Despite a favorable effect of p16-positivity, patients with low neck N2b/N2c, or N3 cervical lymphadenopathy who received CRT alone experienced a higher rate of DM and a trend toward worse survival compared with docetaxel and platinum-based IC (TPF or PF) followed by CRT: 3-year DM was 38% vs 18% (adjusted hazard ratio [HR] = 0.32 [95%CI, 0.13-0.82]), and 3-year overall survival was 67% vs 83% (adjusted HR = 0.48 [95%CI, 0.21-1.12]). Although an unadjusted indirect comparison, these data may suggest that our induction PCE has similar efficacy to conventional docetaxel and platinum-based IC on reducing DM, and demonstrate improved survival in this patient population, who are at high risk of DF: 3-year TTDM and OS in our present study was 16.7% and 83.5%, respectively. Additionally, half of our FAS cases had a hypopharyngeal primary, which is considered a high-risk factor for DM after CRT, which therefore also supports this assumption.

In contrast to tobacco-related squamous cancers, the prognosis of HPV-related cancers is favorable irrespective of the fundamental treatment approach. According to the RTOG 0129 criterion, which is based on the TNM classification and smoking status of LA-SCCHN patients treated with CRT with high-dose CDDP (100 mg/m² on days 1, 22, and 43) alone, at least 88% (14/16) of oropharyngeal cancers of the FAS cases were considered to represent either an intermediate or high-risk population due to their heavy smoking and advanced nodal status. Given that their 3-year OS was expected to range from 46.2% to 70.3% when treated with CRT alone, the addition of induction PCE prior to CRT with CDDP might improve prognosis in these high-risk oropharyngeal cancer patients (2-year OS in the oropharyngeal cancer group: 85.6% in Figure 3A). Additionally, many patients in our study were active drinkers (87.5%, 28/32 of FAS cases), which is also associated with poor survival among SCCHN patients treated CRT. This also indicates that our enrolled patients were definitely at high risk for cancer death when treated with CRT alone, and accordingly represent a patient population who need additional treatment, herein IC.

We evaluated the significance of “good PR” to avoid unnecessary additional therapy after the completion of CRT. In a phase II study of the efficacy and safety of CRT with CDDP plus S-1 in patients with unresectable LA-SCCHN, patients who achieved CR or good PR had significantly better survival than those who did not. Although our present study saw no statistically significant difference between CR and good PR in terms of survival, this was a subgroup analysis in a small number of enrolled patients. It should therefore be evaluated with particular care, and warrants further investigation.

5 | CONCLUSION

In this phase II trial, we found that PCE as IC was feasible and had no effect on compliance of subsequent CRT with CDDP. This in turn suggests that this well-balanced strategy provides considerable efficacy and encouraging survival in a patient population with far advanced and highly aggressive disease, including high-risk oropharyngeal cancer. We consider that these results indicate that induction PCE is a favorable alternative to induction TPF in daily clinical practice for patients with unresectable LA-SCCHN who require more aggressive treatment, herein sequential CRT.

ACKNOWLEDGMENTS

The authors thank the patients and their families, as well as all the investigators and their teams involved in the study. The authors also thank Mr Yuya Suga (Biostatistics Division, Center for Research Administration and Support, National Cancer Center) for his assistance with statistical analysis.

CONFLICT OF INTEREST

KO, SO, and MT received honoraria from Merck Serono. The remaining co-authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

TE contributed to conceptualization, project administration, and writing-review and editing. TO, AH, KO, SM, AN, YS, DM YU, TF, AM, and SO contributed to project administration and resources. SN contributed to statistical analysis and writing-original draft and editing. MT contributed to conceptualization, funding acquisition, project administration, resources, and supervision.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Tomohiro Enokida https://orcid.org/0000-0001-6505-7591

REFERENCES

1. Bray F, Ferlay J, Seerjomatomarai I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Adelstein DJ, Li YI, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol.* 2003;21(1):92-98.

3. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. *Ann Oncol.* 2004;15(8):1179-1186.

4. Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. *Ann Oncol.* 2017;28(9):2206-2212.

5. Haddad RI, Posner M, Hitt R, et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. *Ann Oncol.* 2018;29(5):1130-1140.

6. Ma J, Liu Y, Huang X-L, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. *Oral Oncol.* 2012;48(11):1076-1084.

7. Mak MP, Glisson BS. Is there still a role for induction chemotherapy in locally advanced head and neck cancer? *Curr Opin Oncol.* 2014;26(3):247-251.

8. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med.* 2007;357(17):1705-1715.

9. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med.* 2007;357(17):1695-1704.

10. Janoray G, Pointreau Y, Garaud P, et al. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation. *J Natl Cancer Inst.* 2016;108(4). https://doi.org/10.1093/jnci/djv368

11. Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. *Lancet Oncol.* 2011;12(2):153-159.

12. Budach W, Bölke E, Kammers K, et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. *Radiother Oncol.* 2016;118(2):238-243.

13. Zhang L, Jiang N, Shi Y, Li S, Wang P, Zhao Y. Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis. *Sci Rep.* 2015;5:10798.

14. Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. *J Clin Oncol.* 2014;32(25):2735-2743.

15. Haddad R, O’Neil A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. *Lancet Oncol.* 2013;14(3):257-264.

16. Hitt R, Grau JJ, López-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. *Ann Oncol.* 2014;25(1):216-225.

17. Haddad RI, Posner MR. Induction chemotherapy in head and neck cancer. *J Clin Oncol.* 2009;27(23):e52-e53.

18. Ma J, Liu Y, Yang X, Zhang CP, Zhang ZY, Zhong LP. Induction chemoradiotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. *World J Surg Oncol.* 2013;11:67.

19. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. *J Clin Oncol.* 2010;28(1):8-14.

20. Wanebo HJ, Lee J, Burtness BA, et al. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). *Ann Oncol.* 2014;25(10):2036-2041.

21. Bauman J, Langer C, Quon H, et al. Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. *Exp Ther Med.* 2013;5(4):1247-1253.

22. Zohar S, Teramukai S, Zhou Y. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. *Contemp Clin Trials.* 2008;29(4):608-616.

23. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med.* 2010;363(1):24-35.

24. Adelstein DJ, Moon J, Hanna E, et al. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: a Southwest Oncology Group phase II trial (S0216). *Head Neck.* 2010;32(2):221-228.

25. Buiret G, Combe C, Favrel V, et al. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys.* 2010;77(2):430-437.

26. Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? *J Clin Oncol.* 2004;22(23):4657-4659.

27. Strojan P, Vermorken JB, Beittler JJ, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. *Head Neck.* 2016;38(Suppl 1):E2151-E2158.

28. Haddad RI, Massarelli E, Lee JJ, et al. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys.* 2010;77(2):430-437.

29. Cannon DM, Geye HM, Hartig GK, et al. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. *Head Neck.* 2010;32(2):153-159.

30. Doekeck I, Robbins KT, Vieira F. Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer. *Arch Otolaryngol Head Neck Surg.* 2001;127(11):1315-1318.

31. Riaz N, Setton J, Tam M, et al. Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. *Oral Oncol.* 2014;50(9):863-868.
32. Ballonoff A, Raben D, Rusthoven KE, et al. Outcomes of patients with n3 neck nodes treated with chemoradiation. Laryngoscope. 2008;118(6):995-998.
33. Bhattasali O, Han J, Thompson LDR, Buchschacher GL Jr, Abdalla IA, Iganje S. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease. Oral Oncol. 2018;78:151-155.
34. Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32(30):3365-3373.
35. Huang SH, Perez-Ordonez B, Liu F-F, et al. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(1):276-283.
36. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22(5):1071-1077.
37. Fortin A, Wang CS, Vigneault E. Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2009;74(4):1062-1069.
38. Tahara M, Kiyota N, Mizusawa J, et al. Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). Cancer Sci. 2015;106(6):726-733.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Enokida T, Ogawa T, Homma A, et al. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Med. 2020;9:1671–1682. https://doi.org/10.1002/cam4.2852